DOCSLIB.ORG

Copyrighted Material

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Copyrighted Material Index Note: Pages in italics refer to Figures; those in bold refer to Tables ACE inhibitors (ACEIs), 74, 75 benign prostatic enlargement (BPE), 82 acetylcholine (ACh), 17 benign prostatic hypertropthy (BPH), 149 acromegaly, 86 bilateral retroperitoneal lymphadenectomy and infertility, 156 actinomycosis, 290 bites, 290 activin, 32 bladder extrophy, 236 acute prostatitis, 149 blebbistatin, 185 Addison’s disease, 85–6 brain tumours, primary, 220–1 adenylyl cyclase (AC), 19 bremelanotide, 31, 177 adrenal hormones, 85–6 Brugia malayi, 288 Ageing Male Symptom (AMS), 70 Brugia timori, 288 alfuzosin, 111 Buck’s fascia, 22 alpha‐adrenoreceptor antagonists, 176–7 bulbourethral artery, 22 alpha‐blockers, 58, 75, 76, 213 bupropion, 42 alprostadil, 52, 53, 163, 214 buried penis, 283, 286–7, 287, 288 aminophylline, 183 burns, 239, 290 anastrozole, 154 anatomy, penile, 22–2, 23, 24 calcium channel blockers, 74 vascular anatomy, 22–3 cAMP‐dependent kinase, 19 androgen deficiency, 38 Campylobacter jejuni, 224 androgen deficiency of the aging male (ADAM), 38, 158 Candida albicans, 264 androgen therapy in erectile dysfunction, algorithm, 74 cannabinoids, 18 androgenic anabolic steroids (AAS), 41 Capnocytophaga canimorsus, 290 andropause, 38 carbamazepine, 222 ANDROTEST, 81 cardiometabolic risk, 109 anejaculation, 148–9 cardiovascular risk, 62–7 angiotensin II, 17 algorithm, 67 angiotensin receptor blockers (ARBs), 74–5 artery size hypothesis, 62–3, 64 anorchia, 298 evaluation methods, 66–7 antiepileptic drugs, 222 link with erectile dysfunction, 62–3, 63 anti‐Müllerian syndrome, 297 prediction of CVD events and mortality, 65–6, 65 antipsychotics, 156 temporal relationship, 64–5 anxiety, 120–1, 125–6 cauda equina syndrome, 224 aphallia, 298 cavernosal artery, 23 apomorphine, 18, 42, 51, 177 cavernosal artery insufficiency (CAI), 204 aprostadil, 92–3 cavernosal nerves, 24 aromatase inhibitors, 154 cavernous fibrosis, 95 arteriography, 73 celiac superior mesenteric ganglia (CSMG), 9 ascorbic acid, 154 Center for Epidemiological Studies Depression scale (CES‐D), 247 assisted reproductive technologiesCOPYRIGHTED (ART), 152 cerebrovascular MATERIAL accident (CVA), 109 asymmetric dimethylarginine (ADMA), 114 cGMP‐dependent kinase, 19, 48 autonomic nervous system regulation of erection, 23–5 CHARGE syndrome, 298 avanafil, 176 Chlamydia trachomatis, 288 chronic inflammatory demyelinating polyradiculoneuropathy baclofen, 200, 220 (CIDP), 224 Bacteroides, 290 chronic pelvic pain syndrome, 149 BAY 41‐2272, 184, 216 chronic prostatitis, 149 Beck’s Depression Inventory (BDI), 225 citalopram, 146 BDI II, 125–6 cloacal exstrophy, 298 Male Sexual Dysfunction: A Clinical Guide, First Edition. Edited by Suks Minhas and John Mulhall. © 2017 John Wiley & Sons Ltd. Published 2017 by John Wiley & Sons Ltd. 323 0002882632.indd 323 11/12/2016 11:39:08 AM 324 Index clomiphene citrate, 44, 154 intracavernosal injection therapy (ICI), 178–81 clomipramine, 56, 146 intraurethral therapy, 181–2 codeine, 75 medication effects, 172, 173 co‐dergocrine mesylate, 183 pharmacological therapies, 173–8 colour duplex ultrasound (CDU) of penile arteries, 72–3 testosterone replacement, 173 combination therapy, 53 topical therapies, 182–3 congenital adrenal hyperplasia, 296 drug‐eluting stents, 185–6 coronary artery calcium (CAC) scores, 113 Duplex ultrasonography, 91–9 coronary artery disease (CAD), 62, 109 acute priapism, 95 corpora cavernosa, 22 B‐mode ultrasound, 95 corporal veno‐occlusive dysfunction (CVOD), 204, 272–3 findings, 95–9 corpus spongiosum, 22 method, 94–5 Crohn’s disease288 pre‐surgical test, 92–3, 94 cryotherapy, 310–11 vascular findings in priapism, 97–9, 99 focal cryotherapy, 311 vascular findings, normal and ED, 96–7 whole‐gland cryotherapy, 310–11 Dupuytren’s disease, 246 cryptorchidism, 295 dutasteride, 156, 200 Cushing’s syndrome, 86 dynamic infusion cavernosography and cavernosometry cytomegalovirus, 224 (DICC), 73, 272 dapoxetine, 57, 58, 146–7 EDITS questionnaire, 178 dartos fascia, 22 Eikenella corrodens, 290 dehydroepiandrosterone (DHEA), 86 ejaculation delayed ejaculation (DE), 139–40, 140, 148–9, 148 brain (rat) and spinal generator of ejaculation (SGE), 9 treatment, 148 central nervous system and, 11 depression, 120–1, 126 emission and autonomic nervous system, 10–11 diabetes, erectile dysfunction management and, 210–16 (bulbourethral) Cowper’s glands, 10–11 age, 210 ductus deferens, 10 assessment and investigations, 211–12, 212 prostate, 10 pathophysiology, 210–11 seminal vesicles, 10 prevalence, 210 testis and epididymis, 10 treatment, 212–16, 215 expulsion and somatic nervous system, 11 future, 216 neurophysiology of, 57 gene therapy, 216 orgasm, 12 infection, 216 peripheral nerves and, 9–10 intracavernosal injection, 214–15 afferent neurons, 9 intraurethral suppositories (MUSE), 214 dorsal nerve of the penis, 9 lifestyle, 213 efferent neurons, 9–10 penile prostheses, 215–16 parasympathetic neurons, 10 phosphodiesterase‐5 (PDE5) inhibitors, 213–14 somatic neurons, 10 soluble guanylate cyclase stimulators, 216 sympathetic nerves of the genitals, 9 vacuum devices, 215, 215 sympathetic neurons, 9 Type 1, 210 physiology of, 8–12 Type 2, 39–40, 79, 80, 87–8, 210–11 spinal cord and spinal generator of ejaculation (SGE) (rat), 8–9 1,2‐diacylglycerol (DAG), 19 ejaculatory dysfunction, 1, 139–40 digito‐rectal examination (DRE) of the prostate, 82, 88 endocrinology of male sexual dysfunction, 30–44, 34 digoxin, 200 central organization of sexual function, 30–1 dihydrotestosterone, 32–3 effect of gonadotropins at testicular level, 32–3 2‐dimethyl‐amino‐propionic acid dodecyl ester (DDAIP), 53 endocrine disorders, 33–8, 35 disorders of sex development (DSD), 294–9 androgen deficiency, 38 classification, 295 clinical evaluation, 35–6 common concerns, 294–5 investigations, 37–8 failure of androgen synthesis or receptors, 296–7 physical examination, 37 gonadal dysgenesis, 296 total, bioavailable and free testosterone, 37–8 presentation, 294 kisspeptin‐GPR54‐neurokinin B pathway and regulation receptor defects, 296–7 of GnRH release, 31–2 domperidone, 156 testosterone action, 33 dopamine, 31 treatment, 41–4, 43 dopaminergic agonists, 177 adverse effects, 44 dorsal artery of the penis, 22 choice of preparation, 43–4 doxazosin, 111 general considerations, 41–2 drug therapy for erectile dysfunction, 172–86 other medical therapies, 44 contraindications, 182 testosterone therapy, 42–3 future therapies, 183–6 see also hypogonadism 0002882632.indd 324 11/12/2016 11:39:08 AM Index 325 β‐endorphin, 31 hydrogen sulfide, 185 endothelin‐1, 17 hydroxyurea, 200 Enterococcus species, 264 hypergonadotropic‐hypogonadism, 79, 237 epelsiban, 60 hyperprolactinemia, 39, 44, 79, 83–4 ephedrine, 42, 198 infertility and, 156 epidemiology, 1–5 hyperthyroidism, 84 epidermal growth factor (EGF), 32 infertility and, 156 epilepsy, 222 subclinical, 85 epinephrine, 198 hypogonadism, 1, 2, 30, 33–7, 36, 38, 79–83, 155 Epstein–Barr virus, 224 age and, 5 erectile aids, 207 biochemical evaluation, 82–3 erectile dysfunction, 2 clinical features, 37 age and, 2 diabetes as risk factor, 5 causes, 155 diagnosis, 4–5 definition, 22, 152 early onset, 79 depression and, 2 idiopathic hypogonadotropic (IHH), 79 diagnosis, 1 late‐onset, 38–41, 80 prevalence, 1, 2, 22, 62, 79, 152–4 medical history, 81 risk factors, 2, 70, 71 physical examination, 82 erectile function, definition, 1 prevalence, 4–5 erythromycin, 50 primary (hypergonadotropic), 79, 237 Escherichia coli, 264, 290 questionnaires, 4–5 etilefrine, 198 secondary/central (hypogonadotropic), 79, 155, 156, 237, 298 eutectic mixture of local anesthetics (EMLA), 59 hypogonadotropic hypogonadism (HH), 79, 155, 237, 298 Expanded Disability Status Scale (EDSS) (Kurzke), 223 infertility and, 156 hypoprolactinemia, 84 familial amyloid polyneuropathy (FAP), 224 hypospadias, 236, 295–297–8 filariasis, 288 hypotestosteronemia, 38 finasteride, 156, 200 hypothalamic‐pituitary‐gonadal axis (HPA), 31 fluoxetine, 146 in metabolic syndrome, 111–12 follicle stimulating hormone (FSH), 31, 37 hypothyroidism, 40, 84–5 Fournier’s gangrene, 236, 239, 290 Framingham Risk Score (FRS), 109 idiopathic hypogonadotropic hypogonadism (IHH), 79 free androgen index (FAI), 83 imipramine, 42 frenulum, tight, 73 in vitro fertilization (IVF), 152 Fusobacterium spp. 290 Index of Erectile Function (IIEF), 160, 302 index of premature ejaculation (IPE), 56 gabapentin, 220 infertility, 152–8, 295–6 gamma‐aminobutyric acid (GABA), 18 algorithm for diagnostic evaluation of erectile dysfunction, 160 gender dysphoria (GD), 314 causes and distribution, 153, 154 General Assessment Question (GAQ), 173 erectile dysfunction vs., 154–8 Generalized Anxiety Disorder 7‐item (GAD‐7) scale, 126 etiologies common to erectile dysfunction and, 157 genital cancers, 239 impact on erectile dysfunction, 158–9 germ cell tumors, 294–5 incidence, 152 glans penis, 22 management of erectile dysfunction in CVD, 161, 161–4 gonadoblastoma, 294 overview ofevaluation of erectile dysfunction, 159–60 gonadotropin‐releasing hormone (GnRH), 31, 39 semen analysis, 158–9 granulomatous cheilitis, 288 treatment, 152 growth hormone, 86 inflatable penile prostheses (IPPs), 258, 263 guanylyl cyclase (GC), 19 inhibin, 32 Guillain–Barre syndrome (GBS), 224 inositol, 1,4,5‐trisphosphate (IP3), 19 gynecomastia, 82 insulin‐like growth factor I (IGF‐I), 32, 86 intermesenteric ganglia (IMG), 9 haloperidol, 156 intermesenteric nerves (IMN), 9 Heineke–Mikulicz principle, 250 International Index of Erectile Function (IIEF), 70, 173, 211,
Load more

Recommended publications
  • Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011
    CLASSIFICATION DECISIONS TAKEN BY THE HARMONIZED SYSTEM COMMITTEE FROM THE 47TH TO 60TH SESSIONS (2011 - 2018) WORLD CUSTOMS ORGANIZATION Rue du Marché 30 B-1210 Brussels Belgium November 2011 Copyright © 2011 World Customs Organization. All rights reserved. Requests and inquiries concerning translation, reproduction and adaptation rights should be addressed to [email protected]. D/2011/0448/25 The following list contains the classification decisions (other than those subject to a reservation) taken by the Harmonized System Committee ( 47th Session – March 2011) on specific products, together with their related Harmonized System code numbers and, in certain cases, the classification rationale. Advice Parties seeking to import or export merchandise covered by a decision are advised to verify the implementation of the decision by the importing or exporting country, as the case may be. HS codes Classification No Product description Classification considered rationale 1. Preparation, in the form of a powder, consisting of 92 % sugar, 6 % 2106.90 GRIs 1 and 6 black currant powder, anticaking agent, citric acid and black currant flavouring, put up for retail sale in 32-gram sachets, intended to be consumed as a beverage after mixing with hot water. 2. Vanutide cridificar (INN List 100). 3002.20 3. Certain INN products. Chapters 28, 29 (See “INN List 101” at the end of this publication.) and 30 4. Certain INN products. Chapters 13, 29 (See “INN List 102” at the end of this publication.) and 30 5. Certain INN products. Chapters 28, 29, (See “INN List 103” at the end of this publication.) 30, 35 and 39 6. Re-classification of INN products.
    [Show full text]
  • Chapter 6 Industrial Applications of Multicomponent Reactions (Mcrs)
    University of Groningen Innovative multicomponent reactions and their use in medicinal chemistry Zarganes Tzitzikas, Tryfon IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below. Document Version Publisher's PDF, also known as Version of record Publication date: 2017 Link to publication in University of Groningen/UMCG research database Citation for published version (APA): Zarganes Tzitzikas, T. (2017). Innovative multicomponent reactions and their use in medicinal chemistry. University of Groningen. Copyright Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons). Take-down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum. Download date: 24-09-2021 CHAPTER 6 INDUSTRIAL APPLICATIONS OF MULTICOMPONENT REACTIONS (MCRS) Chapter contained in the Rodriguez-Bonne book Stereoselectve Multple Bond-Forming Transformatons in Organic Synthesis 2015 by John Wiley & Sons, Inc. Tryfon Zarganes – Tzitzikas, Ahmad Yazbak, Alexander Dömling Chapter 6 INTRODUCTION Multcomponent reactons (MCRs) can be defned as processes in which three or more reactants introduced simultaneously are combined through covalent bonds to form a single product, regardless of the mechanisms and protocols involved.[1] Many basic MCRs are name reactons, for example, Ugi,[2] Passerini,[3] van Leusen,[4] Strecker,[5] Hantzsch,[6] Biginelli,[7] or one of their many variatons.
    [Show full text]
  • FOGSI FOCUS PTL-Final
    Editors : President: Jaideep Malhotra Dr. Rishma Dhillon Pai Narendra Malhotra Contributors Preface Dr. Asha Reddy Dr. Ruchika Garg, Assistant Professor obs. & gynae, Dr. Apoorva Pallam Reddy, SN Medical College, Agra Consultant Preterm Labour is one of the 5 ‘P’ problem of pregnancy. Dr. Rajalaxmi Walavalkar, Dr. Anuradha Khar, Senior consultant, Cocoon fertility centre, Despite of understanding the problem, the prevalence is static Director, nurture IVF, Bangalore Thane even in developed countries. Dr. Arshi Iqbal, Dr. Raju Sahetya, Director Arshi fertility, Kota, Consultant obs. and gynae, Hinduja The problem of being born to soon is more in babies born Rajasthan Hospital, Mumbai before 33 weeks gestation and babies born in developing countries with low resource settings. Dr. Chaitanya Ganapule, Dr. Rakhi Singh, Pearl IVF, Pune Director Abalone clinic and IVF centre, Noida This multiauthored FOGSI focus is a comprehensive Dr. Kavita N Singh, collection of all aspects of Preterm Labour. The authors have Associate Professor, NSCB Medical Dr. Shalini Chauhan, done a great job in rehearsing each topic and compiling College, Jabalpur Assistant Professor, PGI Tanda relevant information which will be useful to the practising Dr. Kavitha Gautam, Dr. Seema Pandey, obstetrician. Director Bloom fertility, Chennai Director Seema Hospital and Eva fertility centre, Azamgarh Dr. Neema Acharya, We hope all FOGSIANS will benefit from this manuscript. Professor, DMIMS DU, Wardha Dr. Swati Upadhyay, SR KIMS, Trivendrum Dr. Niharika Malhotra Happy Reading Dr. Uma Pandey, Dr. Parul Mittal, specialist obs. & gynae, Professor obs. & gynae, IMS BHU, Aster D.M. Healthcare, Dubai, UAE Varanasi Jaideep Malhotra, Narendra Malhotra Dr. Paresh K Solanki Dr.
    [Show full text]
  • Oxytocin Receptor OXTR
    Oxytocin Receptor OXTR The oxytocin receptor belongs to the G-protein-coupled seven-transmembrane receptor superfamily. Its main physiological role is regulating the contraction of uterine smooth muscle at parturition and the ejection of milk from the lactating breast. The oxytocin receptors are activated in response to binding oxytocin and a similar nonapeptide, vasopressin. Oxytocin receptor triggers Gi or Gq protein-mediated signaling cascades leading to the regulation of a variety of neuroendocrine and cognitive functions. Oxytocin is a nonapeptide of the neurohypophyseal protein family that binds specifically to the oxytocin receptor to produce a multitude of central and peripheral physiological responses. In vivo, oxytocin acts as a paracrine and/or autocrine mediator of multiple biological effects. These effects are exerted primarily through interactions with G-protein-coupled oxytocin/vasopressin receptors, which, via Gq and Gi, stimulate phospholipase C-mediated hydrolysis of phosphoinositides. www.MedChemExpress.com 1 Oxytocin Receptor Agonists & Antagonists Atosiban Atosiban acetate (RW22164; RWJ22164) Cat. No.: HY-17572 (RW22164 acetate; RWJ22164 acetate) Cat. No.: HY-17572A Atosiban (RW22164; RWJ22164) is a nonapeptide Atosiban acetate (RW22164 acetate;RWJ22164 competitive vasopressin/oxytocin receptor acetate) is a nonapeptide competitive antagonist, and is a desamino-oxytocin analogue. vasopressin/oxytocin receptor antagonist, and is a Atosiban is the main tocolytic agent and has the desamino-oxytocin analogue. Atosiban is the main potential for spontaneous preterm labor research. tocolytic agent and has the potential for spontaneous preterm labor research. Purity: 99.09% Purity: 99.92% Clinical Data: Launched Clinical Data: Launched Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg Carbetocin Epelsiban Cat.
    [Show full text]
  • Chemical Properties Biological Description Solubility Information
    Data Sheet (Cat.No.T11502) Epelsiban Chemical Properties CAS No.: 872599-83-2 Formula： C30H38N4O4 Molecular Weight： 518.65 Appearance： N/A Storage： 0-4℃ for short term (days to weeks), or -20℃ for long term (months). Biological Description Description Epelsiban is a selective and orally bioavailable oxytocin receptor antagonist (pKi: 9.9 for human oxytocin receptor). Targets(IC50) human oxytocin receptor: 192 nM In vitro Epelsiban shows no significant P450 inhibition. Epelsiban is a potent oxytocin receptor, with a pKi of 9.9 for human oxytocin receptor, >31000-fold selectivity over all three human vasopressin receptors hV1aR (pKi, <5.2), hV2R (pKi, <5.1), and hV1bR (pKi, 5.4). In vivo Epelsiban has low levels of intrinsic clearance against the microsomes of rat, dog, and cynomolgus monkey, good bioavailability (55%), but is negative in the genotoxicity screens with a satisfactory oral safety profile in female rats. Epelsiban shows an IC50 of 192 nM for oxytocin receptor in rats. Solubility Information Solubility < 1 mg/ml refers to the product slightly soluble or insoluble Preparing Stock Solutions 1mg 5mg 10mg 1 mM 1.928 mL 9.64 mL 19.281 mL 5 mM 0.386 mL 1.928 mL 3.856 mL 10 mM 0.193 mL 0.964 mL 1.928 mL 50 mM 0.039 mL 0.193 mL 0.386 mL Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. The storage conditions and period of the stock solution: - 80 ℃ for 6 months; - 20 ℃ for 1 month.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Premature Ejaculation
    F1000Research 2017, 6(F1000 Faculty Rev):2084 Last updated: 15 NOV 2019 REVIEW Premature ejaculation: challenging new and the old concepts [version 1; peer review: 2 approved] Odunayo Kalejaiye 1, Khaled Almekaty1,2, Gideon Blecher1, Suks Minhas1 1Department of Andrology, University College London Medical School, London, W1G 8PH, UK 2Urology Department, University of Tanta, Tanta, Egypt First published: 04 Dec 2017, 6(F1000 Faculty Rev):2084 ( Open Peer Review v1 https://doi.org/10.12688/f1000research.12150.1) Latest published: 04 Dec 2017, 6(F1000 Faculty Rev):2084 ( https://doi.org/10.12688/f1000research.12150.1) Reviewer Status Abstract Invited Reviewers Premature ejaculation remains a difficult condition to manage for patients, 1 2 their partners, and the clinician. Whilst prevalence rates are estimated to be 20–40%, determining a diagnosis of premature ejaculation is difficult, as the version 1 definition remains both subjective and ill-defined in the clinical context. As published our understanding of the ejaculatory pathway has improved, new 04 Dec 2017 opportunities to treat the condition have evolved with mixed results. In this review, we explore some of these controversies surrounding the aetiology, diagnosis, and treatment of this condition and discuss potential novel F1000 Faculty Reviews are written by members of therapeutic options. the prestigious F1000 Faculty. They are Keywords commissioned and are peer reviewed before Premature ejaculation, Treatment, Aetiology, Diagnosis, Physiology publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations. 1 Ege Can Serefoglu, UroKlinik Urology Center, Zerrin Sk 2, Levent, 34330, Turkey 2 Emmanuele A Jannini, University of L'Aquila, L'Aquila, Italy Any comments on the article can be found at the end of the article.
    [Show full text]
  • Protein–Protein Interactions in Drug Discovery
    56 Methods and Principles in Medicinal Chemistry Dömling Edited by Alexander Dömling Treating protein-protein interactions as a novel and highly promising class of drug targets, this volume introduces the underlying strategies step by step, from the biology of PPIs to biophysical and computational methods for their investigation. (Ed.) The main part of the book describes examples of protein targets for which small molecule modulators have been developed, covering such Protein–Protein diverse fields as cancer, autoimmune disorders and infectious diseases. Tailor-made for the practicing medicinal chemist, this ready reference includes a wide selection of case studies taken straight from the develop- ment pipeline of major pharmaceutical companies to illustrate the power Interactions in and potential of this approach. From the contents: G Prediction of intra- and inter-species protein-protein interactions Drug Discovery facilitating systems biology studies G Modulators of protein-protein interactions: the importance of three-dimensionality G Interactive technologies for leveraging the known chemistry of anchor residues G SH3 domains as drug targets G P53 MDM2 antagonists: towards non genotoxic anticancer Protein–Protein Interactions treatments in Drug Discovery Volume 56 G Inhibition of LFA-1/ICAM interaction for treatment of autoimmune diseases G The PIF-binding pocket of AGC kinases Series Editors: G Peptidic inhibitors of protein-protein interactions for cell adhesion R.Mannhold, receptors G The REPLACE strategy for generating non-ATP competitive H.Kubinyi, inhibitors of cell-cycle protein kinases G.Folkers and more Alexander Dömling studied Chemistry and Biology at the Technical University Munich, Germany. After obtaining his PhD under the supervision of Ivar Ugi, he spent a postdoctoral year at the Scripps Research Institute in La Jolla (USA) in the group of Nobel Laureate Barry Sharpless.
    [Show full text]
  • Nouvelles Réactions De Contraction De Cycle: Outils Pour La Construction D
    Nouvelles réactions de contraction de cycle : outils pour la construction d’édifices organisés Guilhem Chaubet To cite this version: Guilhem Chaubet. Nouvelles réactions de contraction de cycle : outils pour la construction d’édifices organisés. Génie chimique. Université Montpellier II - Sciences et Techniques du Languedoc, 2013. Français. NNT : 2013MON20119. tel-01066789 HAL Id: tel-01066789 https://tel.archives-ouvertes.fr/tel-01066789 Submitted on 22 Sep 2014 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Délivré par l’Université Montpellier 2 Préparée au sein de l’école doctorale Sciences Chimiques Balard Et de l’ Institut des Biomolécules Max Mousseron -UMR5247 Spécialité : Ingénierie Moléculaire Présentée par Guilhem CHAUBET Nouvelles réactions de contraction de cycle : outils pour la construction d'édifices organisés Soutenue le 04 décembre 2013 devant le jury composé de Dr Gilles Guichard, Directeur de Recherche, Rapporteur Université de Bordeaux 1 Dr Jean-Luc Parrain, Directeur de Recherche, Rapporteur Université d’Aix -Marseille Dr Jean
    [Show full text]
  • Differences in the Contractility of Human Isolated
    e356 THE JOURNAL OF UROLOGYâ Vol. 193, No. 4S, Supplement, Saturday, May 16, 2015 CONCLUSIONS: This is the first demonstration of a contractile effect of OT in human prostatic urethra through specific OT receptors. In addition, OT appears to produce larger responses in tissue from BPH patients. Source of Funding: GlaxoSmithKline PLC MP31-04 CD8D T CELLS PROMOTE PROLIFERATION OF BENIGN PROSTATIC HYPERPLASIA EPITHELIAL CELLS IN THE CONDITION OF LOW ANDROGEN Yang Yang*, Shuai Hu, Yu Fan, Yun Cui, Mengkui Sun, Jie Jin, Beijing, China, People’s Republic of INTRODUCTION AND OBJECTIVES: Clinical studies sug- gested that androgen might be associated with infiltrating T cells in prostate of benign prostatic hyperplasia (BPH) patients. Previous studies of our laboratory (data from 64 cases of BPH patients with/ without finasteride treatment) have shown that low intra-prostatic dihy- Source of Funding: The study was supported in part by Grants drotestosterone (DHT) induced the BPH epithelial cells to recruit CD8þ in aid from the Ministry of Education, Science, and Culture of T cells via modulation of CCL5 secretion. However, the consequences Japan (#24592431, 20591880). of CD8þ T cells towards prostate tissues remained unclear. There- fore,the present study aimed to investigate the effects of CD8þ T cells on BPH epithelial cells in low DHT condition. MP31-03 METHODS: In vitro co-culture system was used to detect im- pacts of CD8þ T cell line–Molt-3 cells on the BPH epithelial cell line– DIFFERENCES IN THE CONTRACTILITY OF HUMAN ISOLATED Bph-1 cells in the low level of DHT condition (medium was treated with PROSTATIC URETHRA TO OXYTOCIN AND NOREPINEPHRINE IN 10% charcoal fetal bovine serum).
    [Show full text]
  • Oxytocin As an Appetite Suppressant That Reduces Feeding Reward
    http://researchcommons.waikato.ac.nz/ Research Commons at the University of Waikato Copyright Statement: The digital copy of this thesis is protected by the Copyright Act 1994 (New Zealand). The thesis may be consulted by you, provided you comply with the provisions of the Act and the following conditions of use: Any use you make of these documents or images must be for research or private study purposes only, and you may not make them available to any other person. Authors control the copyright of their thesis. You will recognise the author’s right to be identified as the author of the thesis, and due acknowledgement will be made to the author where appropriate. You will obtain the author’s permission before publishing any material from the thesis. Oxytocin as an appetite suppressant that reduces feeding reward A thesis submitted in partial fulfilment of the requirements for the degree of Doctor of Philosophy in Biological Sciences at The University of Waikato by Florence M. Herisson _________ The University of Waikato 2016 2 Abstract In the environment in which palatable and highly caloric foods are readily available, eating behavior is oftentimes not dictated by the necessity to replenish lacking energy, but rather by the pleasure of consumption. Centrally acting oxytocin (OT) is known to promote termination of feeding to protect internal milieu by preventing excessive stomach distension, hyperosmolality and ingestion of toxins. Initial evidence suggests that another possible role for OT in mechanisms governing food intake is to reduce consumption of select palatable tastants. This thesis explores the question whether OT is as an appetite suppressant that reduces feeding reward.
    [Show full text]
  • The Oxytocin Receptor: from Intracellular Signaling to Behavior
    Physiol Rev 98: 1805–1908, 2018 Published June 13, 2018; doi:10.1152/physrev.00031.2017 THE OXYTOCIN RECEPTOR: FROM INTRACELLULAR SIGNALING TO BEHAVIOR Benjamin Jurek and Inga D. Neumann Department of Behavioural and Molecular Neurobiology, Institute of Zoology, University of Regensburg, Regensburg, Germany Jurek B, Neumann ID. The Oxytocin Receptor: From Intracellular Signaling to Behav- ior. Physiol Rev 98: 1805–1908, 2018. Published June 13, 2018; doi:10.1152/ physrev.00031.2017.—The many facets of the oxytocin (OXT) system of the brain and periphery elicited nearly 25,000 publications since 1930 (see FIGURE 1, as listed in PubMed), which revealed central roles for OXT and its receptor (OXTR) in reproduction, Land social and emotional behaviors in animal and human studies focusing on mental and physical health and disease. In this review, we discuss the mechanisms of OXT expression and release, expression and binding of the OXTR in brain and periphery, OXTR-coupled signaling cascades, and their involvement in behavioral outcomes to assemble a comprehensive picture of the central and peripheral OXT system. Traditionally known for its role in milk let-down and uterine contraction during labor, OXT also has implications in physiological, and also behavioral, aspects of reproduc- tion, such as sexual and maternal behaviors and pair bonding, but also anxiety, trust, sociability, food intake, or even drug abuse. The many facets of OXT are, on a molecular basis, brought about by a single receptor. The OXTR, a 7-transmembrane G protein-coupled receptor capable of binding ␣ ␣ to either G i or G q proteins, activates a set of signaling cascades, such as the MAPK, PKC, PLC, or CaMK pathways, which converge on transcription factors like CREB or MEF-2.
    [Show full text]